Metallographic in situ hybridization

Human Pathology

Volumn 38, Issue 8, 2007, Pages 1145-1159

  Powell, Richard D ^a   Pettay, James D ^b,c   Powell, William C ^d   Roche, Patrick C ^d   Grogan, Thomas M ^d   Hainfeld, James F ^a   Tubbs, Raymond R ^b,c  

^a Nanoprobes Incorporated   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Automated slide staining; Autometallography; Breast cancer; Enzyme metallography; HER2; In situ hybridation

Indexed keywords

BIOTIN; CHROMOGENIC SUBSTRATE; COLLOIDAL GOLD; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOPROPAMIDE IODIDE; STREPTAVIDIN;

ARTICLE; AUTOMETALLOGRAPHY; BIOPSY; BREAST CARCINOMA; CHROMOSOME 17; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PROTEIN EXPRESSION; STAINING;

ADENOCARCINOMA; BREAST NEOPLASMS; ENZYMES; FEMALE; GOLD COLLOID; HUMANS; IN SITU HYBRIDIZATION; NUCLEIC ACIDS; RECEPTOR, ERBB-2; SILVER COMPOUNDS; SILVER STAINING;

EID: 34447312475     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2007.05.004     Document Type: Article

References (124)

1. Watson J.D., and Crick F.H.C. Molecular structure of nucleic acids-a structure for deoxyribose nucleic acids. Nature (London) 171 (1953) 737-738
2. de Jong H. Visualizing DNA domains and sequences by microscopy: a fifty-year history of molecular cytogenetics. Genome 2003;46:943-6.
3. Caspersson T., Lindsten J., Lomakka G., Moller A., and Zech L. The use of fluorescence techniques for the recognition of mammalian chromosomes and chromosome regions. Int Rev Exp Pathol 11 (1972) 1-72
4. Pardue M.L., and Gall J.G. Molecular hybridization of radioactive DNA to the DNA of cytological preparations. Proc Natl Acad U S A Sci 64 (1969) 600-604
5. John H.A., Birnstiel M.L., and Jones K.W. RNA-DNA hybrids at the cytological level. Nature 223 (1969) 582-587
6. Buongiorno-Nardelli M., and Amaldi F. Autoradiographic detection of molecular hybrids between RNA and DNA in tissue sections. Nature 225 (1970) 946-948
7. Trask B.J. Fluorescence in situ hybridization: applications in cytogenetics and gene mapping. Trends Genet 7 (1991) 149-154
8. Bauman J.G., Wiegant J., Borst P., and van Duijn P. A new method for fluorescence microscopical localization of specific DNA sequences by in situ hybridization of fluorochromelabelled RNA. Exp Cell Res 128 (1980) 485-490
9. Rudkin G.T., and Stollar B.D. High resolution detection of DNA-RNA hybrids in situ by indirect immunofluorescence. Nature 265 (1977) 472-473
10. Nederlof P.M., van der Flier S., Wiegant J., et al. Multiple fluorescence in situ hybridization. Cytometry 11 (1990) 126-131
11. Qian X., and Lloyd R.V. Recent developments in signal amplification methods for in situ hybridization. Diagn Mol Pathol 12 (2003) 1-13
12. van de Corput M.P., Dirks R.W., van Gijlswijk R.P., van de Rijke F.M., and Raap A.K. Fluorescence in situ hybridization using horseradish peroxidase-labeled oligodeoxynucleotides and tyramide signal amplification for sensitive DNA and mRNA detection. Histochem Cell Biol 110 (1998) 431-437
13. Kerstens H.M., Poddighe P.J., and Hanselaar A.G. A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. J Histochem Cytochem 43 (1995) 347-352
14. Tsuda H. HER2 (c-erbB-2) test update: present status and problems. Breast Cancer 13 (2006) 236-248
15. Qian X., Guerrero R.B., Plummer T.B., Alves V.F., and Lloyd R.V. Detection of hepatitis C virus RNA in formalin-fixed paraffin-embedded sections with digoxigenin-labeled cRNA probes. Diagn Mol Pathol 13 (2004) 9-14
16. Abdulkarim A.S., Petrovic L.M., Kim W.R., Angulo P., Lloyd R.V., and Lindor K.D. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?. J Hepatol 40 (2004) 380-384
17. Hayden R.T., Isotalo P.A., Parrett T., et al. In situ hybridization for the differentiation of Aspergillus, Fusarium, and Pseudallescheria species in tissue section. Diagn Mol Pathol 12 (2003) 21-26
18. Masood S., Bui M.M., Yung J.F., et al. Reproducibility of LSI HER-2/neu SpectrumOrange and CEP 17 SpectrumGreen dual color deoxyribonucleic acid probe kit. For enumeration of gene amplification in paraffin-embedded specimens: a multicenter clinical validation study. Ann Clin Lab Sci 28 (1998) 215-223
19. Detailed guide: breast cancer. What are the key statistics for breast cancer? American Cancer Society, http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_breast_cancer_5.asp?sitearea= (Revised September 18, 2006).
20. Nofech-Mozes S., Spayne J., Rakovitch E., and Hanna W. Prognostic and predictive molecular markers in DCIS: a review. Adv Anat Pathol 12 (2005) 256-264
21. McGuire W.L. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 10 (1987) 5-9
22. Schechter A.L., Stern D.F., Vaidyanathan L., et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312 (1984) 513-516
23. Chen L., Zhang W., Fregien N., and Pierce M. The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products. Oncogene 17 (1998) 2087-2093
24. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
25. Toikkanen S., Helin H., Isola J., and Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10 (1992) 1044-1048
26. Descotes F., Pavy J.J., and Adessi G.L. Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Res 13 (1993) 119-124
27. Makar A.P., Desmedt E.J., De Potter C.R., Vanderheyden J.S., and Schatteman E.A. Neu (C-erbB-2) oncogene in breast cancer and its possible association with the risk of distant metastases. A retrospective study and review of literature. Acta Oncol 29 (1990) 931
28. Tiwari R.K., Borgen P.I., Wong G.Y., Cordon-Cardo C., and Osborne M.P. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12 (1992) 419-425
29. Seshadri R., Horsfall D.J., Firgaira F., et al. The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group. Int J Cancer 56 (1994) 61-65
30. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
31. Allred D.C., Clark G.M., Tandon A.K., et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10 (1992) 599-605
32. Chang J., Clark G.M., Allred D.C., Mohsin S., Chamness G., and Elledge R.M. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97 (2003) 545-553
33. Zeillinger R., Kury F., Czerwenka K., et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4 (1989) 109-114
34. Bacus S.S., Zelnick C.R., Plowman G., and Yarden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am J Clin Pathol 102 (1994) S13-S24
35. Pegram M.D., Finn R.S., Arzoo K., Beryt M., Pietras R.J., and Slamon D.J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15 (1997) 537-547
36. Fornier M, Risio M, Van Poznak C, Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Huntingt). 2002;16:1340-8, 1351-52; discussion, 1352, 1355-58
37. Konecny G, Slamon DJ. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Huntingt). 2002;16:1576, 1578
38. Pegram M.D., and Slamon D.J. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26 4 Suppl 12 (1999) 89-95
39. Fornier M.N., Seidman A.D., Schwartz M.K., et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16 (2005) 234-239
40. Feldman A.M., Lorell B.H., and Reis S.E. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102 (2000) 272-274
41. Nissenblatt M.J., and Karp G.I. Bleeding risk with trastuzumab (Herceptin) treatment. JAMA 282 (1999) 2299-2301
42. Chen Y., Dong J., Lu Y., and McGee J.O. Quantitative detection of amplification of proto-oncogenes in breast cancer. Chin Med J (Eng) 108 (1995) 849-854
43. Donovan-Peluso M., Contento A.M., Tobon H., Ripepi B., and Locker J. Oncogene amplification in breast cancer. Am J Pathol 138 (1991) 835-845
44. Valeron P.F., Chirino R., Fernandez L., et al. Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. Int J Cancer 65 (1996) 129-133
45. van de Vijver M.J., Mooi W.J., Wisman P., Peterse J.L., and Nusse R. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene 2 (1988) 175-178
46. Molina R., Ciocca D.R., Tandon A.K., et al. Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 12 (1992) 1965-1971
47. Press M.F., Pike M.C., Chazin V.R., et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53 (1993) 4960-4970
48. Birner P., Oberhuber G., Stani J., et al. Austrian Breast & Colorectal Cancer Study Group. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7 (2001) 1669-1675
49. O'Malley F.P., Parkes R., Latta E., et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 115 (2001) 504-511
50. Pauletti G., Godolphin W., Press M.F., and Slamon D.J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13 (1996) 63-72
51. Fernandez J.L., Goyanes V., Lopez-Fernandez C., Buno I., and Gosalvez J. Quantification of C-ERB-B2 gene amplification in breast cancer cells using fluorescence in situ hybridization and digital image analysis. Cancer Genet Cytogenet 86 (1996) 18-21
52. Press M.F., Bernstein L., Thomas P.A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15 (1997) 2894-2904
53. Xing W.R., Gilchrist K.W., Harris C.P., Samson W., and Meisner L.F. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 39 (1996) 203-212
54. Gonzalez-Angulo A.M., Hortobagyi G.N., and Esteva F.J. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11 (2006) 857-867
55. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
56. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
57. Coudert B.P., Arnould L., Moreau L., et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17 (2006) 409-414
58. Limentani S.A., Brufsky A.M., Erban J.K., Jahanzeb M., and Lewis D. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 25 (2007) 1232-1238
59. Gouvea A.P., Milanezi F., Olson S.J., Leitao D., Schmitt F.C., and Gobbi H. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol 14 (2006) 103-108
60. Baak J.P., Chin D., van Diest P.J., Ortiz R., Matze-Cok P., and Bacus S.S. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab Invest 64 (1991) 215-223
61. Press M.F., Hung G., Godolphin W., and Slamon D.J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54 (1994) 2771-2777
62. Johnson R.C., Ricci Jr. A., Cartun R.W., Ackroyd R., and Tsongalis G.J. p185HER2 overexpression in human breast cancer using molecular and immunohistochemical methods. Cancer Invest 18 (2000) 336-342
63. Wang S., Saboorian M.H., Frenkel E., Hynan L., Gokaslan S.T., and Ashfaq R. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 53 (2000) 374-381
64. Tubbs R.R., Pettay J.D., Roche P.C., Stoler M.H., Jenkins R.B., and Grogan T.M. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19 (2001) 2714-2721
65. Seidman A.D., Fornier M.N., Esteva F.J., et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19 (2001) 2587-2595
66. Tedesco K.L., Thor A.D., Johnson D.H., et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22 (2004) 1071-1077
67. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
68. Press M.F., Slamon D.J., Flom K.J., Park J., Zhou J.Y., and Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20 (2002) 3095-3105
69. Lal P., Salazar P.A., Hudis C.A., Ladanyi M., and Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 121 (2004) 631-636 [Erratum in: Am J Clin Pathol, 2004;6:58
70. Ma Y., Lespagnard L., Durbecq V., et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11 (2005) 4393-4399
71. Persons D.L., Tubbs R.R., Cooley L.D., et al. HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med 130 (2006) 325-331
72. Dal Lago L., Durbecq V., Desmedt C., et al. Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 5 (2006) 2572-2579
73. Vera-Roman J.M., and Rubio-Martinez L.A. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med 128 (2004) 627-633
74. Tanner M., Gancberg D., Di Leo A., et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 157 (2000) 1467-1472
75. Dandachi N., Dietze O., and Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest 82 (2002) 1007-1014
76. Gupta D., Middleton L.P., Whitaker M.J., and Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 119 (2003) 381-387
77. Isola J., Tanner M., Forsyth A., Cooke T.G., Watters A.D., and Bartlett J.M. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res 10 (2004) 4793-4798
78. Peiro G., Mayr D., Hillemanns P., Lohrs U., and Diebold J. Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcome. Mod Pathol 17 (2004) 227-287
79. Gong Y., Gilcrease M., and Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol 18 (2005) 1015-1021
80. Loring P., Cummins R., O'Grady A., and Kay E.W. HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol 13 (2005) 194-200
81. Bhargava R., Lal P., and Chen B. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?. Am J Clin Pathol 123 (2005) 237-243
82. Nitta H., Christensen K., and Grogan T.M. Automated colormetric tyramide signal amplification in situ hybridization (TISH) detection of single HER-2/neu oncogene copies. Acta Histochem Cytochem 35 (2002) 224
83. Laakso M., Tanner M., and Isola J. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours. J Pathol 210 (2006) 3-9
84. Faulk W.P., and Taylor G.M. An immunocolloid method for the electron microscope. Immunochemistry 8 (1971) 1081-1083
85. Handley D.A. The development and application of colloidal gold as a microscopic probe; methods for synthesis of colloidal gold. In: Hayat M.A. (Ed). Colloidal gold: principles, methods and applications (1989), Academic Press, San Diego, CA 1-33
86. Wu M., and Davidson N. Transmission electron microscopic method for gene mapping on polytene chromosomes by in situ hybridization. Proc Natl Acad USA Sci 78 (1981) 7059-7063
87. Hutchison N.J., Langer-Safer P.R., Ward D.C., and Hamkalo B.A. In situ hybridization at the electron microscope level: hybrid detection by autoradiography and colloidal gold. J Cell Biol 95 (1982) 609-618
88. Ferguson D.J., Burns J., Harrison D., Jonasson J.A., and McGee J.O. Chromosomal localization of genes by scanning electron microscopy using in situ hybridization with biotinylated probes: Y chromosome repetitive sequences. J. Histochem 18 (1986) 266-270
89. Danscher G. Localization of gold in biological tissue. A photochemical method for light and electronmicroscopy. Histochemistry 71 (1981) 81-88
90. Danscher G., and Norgaard J.O. Light microscopic visualization of colloidal gold on resin-embedded tissue. J Histochem Cytochem 31 (1983) 1394-1398
91. Hacker G.W., Springall D.R., Van Noorden S., Bishop A.E., Grimelius L., and Polak J.M. The immunogold-silver staining method. A powerful tool in histopathology. Virchows Arch A Pathol Anat Histopathol 406 (1985) 449-461
92. Hacker G.W., Graf A.H., Hauser-Kronberger C., et al. Application of silver acetate autometallography and gold-silver staining methods for in situ DNA hybridization. Chin Med J (Engl) 106 (1993) 83-92
93. Hainfeld J.F., and Powell R.D. New frontiers in gold labeling. J Histochem Cytochem 48 (2000) 471-480
94. Hainfeld J.F. STEM analysis of Janssen Auroprobe One. In: Bailey G.W. (Ed). Proc. XII Int. Cong. Elec. Microsc (1990), San Francisco Press, San Francisco, CA 954-955
95. Behnke O., Ammitzboll T., Jessen H., et al. Non-specific binding of protein-stabilized gold sols as a source of error in immunocytochemistry. Eur J Cell Biol 41 (1986) 326-338
96. Kramarcy N.R., and Sealock R. Commercial preparations of colloidal gold-antibody complexes frequently contain free active antibody. J Histochem Cytochem 39 (1990) 37-39
97. Sun X.J., Tolbert L.P., and Hildebrand J.G. Using laser scanning confocal microscopy as a guide for electron microscopic study: a simple method for correlation of light and electron microscopy. J Histochem Cytochem 43 (1995) 329-335
98. Hainfeld J.F., and Furuya F.R. Silver enhancement of Nanogold and Undecagold. In: Hayat M.A. (Ed). Immunogold-silver staining: principles, methods and applications (1995), CRC Press, Boca Raton, FL 71-96
99. Hacker G.W., Zehbe I., Hainfeld J., et al. High-performance Nanogold in situ hybridization and in situ PCR. Cell Vision 3 (1996) 209-214
100. Zehbe I., Hacker G.W., Su H., Hauser-Kronberger C., Hainfeld J.F., and Tubbs R. Sensitive in situ hybridization with catalyzed reporter deposition, streptavidin-Nanogold, and silver acetate autometallography: detection of single-copy human papillomavirus. Am J Pathol 150 (1997) 1553-1561
101. Hacker G.W., Hauser-Kronberger C., Zehbe I., et al. In situ localization of DNA and RNA sequences: super-sensitive in situ hybridization using streptavidin-Nanogold-silver staining: minireview, protocols and possible applications. Cell Vision 4 (1997) 54-65
102. Hainfeld J.F., and Powell R.D. Silver- and gold-based autometallography of Nanogold. In: Hacker G.W., and Gu J. (Eds). Gold and silver staining: techniques in molecular morphology (2002), CRC Press, Boca Raton 29-46
103. Owen G.R., Meredith D.O., Ap Gwynn I., and Richards R.G. Enhancement of immunogold-labelled focal adhesion sites in fibroblasts cultured on metal substrates: problems and solutions. Cell Biol Int 25 (2001) 1251-1259
104. Cheung A.L., Graf A.H., Hauser-Kronberger C., Dietze O., Tubbs R.R., and Hacker G.W. Detection of human papillomavirus in cervical carcinoma: comparison of peroxidase, Nanogold, and catalyzed reporter deposition (CARD)-Nanogold in situ hybridization. Mod Pathol 12 (1999) 689-696
105. Powell R.D., Joshi V.N., Halsey C.M.R., et al. Combined Cy3/Nanogold conjugates for immunocytochemistry and in situ hybridization. In: Bailey G.W., Jerome W.G., McKernan S., Mansfield J.F., and Price R.L. (Eds). Microsc Microanal, 5 (Suppl. 2: Proceedings) (1999) 478-479
106. Tubbs R., Pettay J., Skacel M., et al. Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. Am J Pathol 160 (2002) 1589-1595
107. Tubbs R., Skacel M., Pettay J., et al. Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma. Am J Surg Pathol 26 (2002) 908-913
108. Hicks D, Ruddy T, Downs-Kelly E, et al. Quantitative image analysis of GOLDFISH, (a first generation gold-facilitated autometallographic bright field in-situ hybridization assay) for HER2 gene amplification in invasive breast cancer. 26th San Antonio Breast Cancer Symposium; 2003; poster #611.
109. Hainfeld J.F., Eisen R.N., Tubbs R.R., and Powell R.D. Enzymatic metallography: a simple new staining method. In: Lyman C.E., Albrecht R.M., Carter C.B., Dravid V.P., Herman B., and Schatten H. (Eds). Microsc Microanal, 8 (Suppl. 2: Proceedings) (2002) 916 CD
110. Hainfeld J.F., Powell R.D., and Hacker G.W. Nanoparticle molecular labels. In: Mirkin C.A., and Niemeyer C.M. (Eds). Nanobiotechnology (2004), Wiley-VCH, Weinheim, Germany 353-386 [ch. 23]
111. Tubbs R., Pettay J., Hicks D., et al. Novel bright field molecular morphology methods for detection of HER2 gene amplification. J Mol Histol 35 (2004) 589-594
112. Tubbs R.R., Pettay J., Skacel M., et al. Gold and silver-facilitated metallographic in situ hybridization procedures for detection of HER2 gene amplification. In: Hacker G.W., and Tubbs R.R. (Eds). Molecular morphology in human tissues (2005), CRC Press, Boca Raton, FL 101-106 [ch. 5]
113. Tubbs R., Pettay J., Powell R., et al. Enzyme metallography (EnzMet): a novel second generation bright field assay for detection of HER2 gene amplification in breast carcinoma. J Mol Diagn (AMP 2003 Meeting Abstracts) 5 (2003) 279
114. Bonin S., Petrera F., Rosai J., and Stanta G. DNA and RNA obtained from Bouin's fixed tissues. J Clin Pathol 58 (2005) 313-316
115. Sato T., Abe K., Kurose A., Uesugi N., Todoroki T., and Sasaki K. Amplification of the c-erbB-2 gene detected by FISH in gastric cancers. Pathol Int 47 (1997) 179-182
116. Ishikawa T., Kobayashi M., Mai M., Suzuki T., and Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol 151 (1997) 761-768
117. Tubbs R., Pettay J., Powell R., et al. High-resolution immunophenotyping of subcellular compartments in tissue microarrays by enzyme metallography. Appl Immunohistochem Mol Morphol 13 (2005) 371-375
118. Tubbs R.R., Pettay J., Roche P., et al. Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression. J Mol Diagn 2 (2000) 78-83
119. Downs-Kelly E., Pettay J., Hicks D., et al. Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol 29 (2005) 1505-1511
120. Skacel M., Skilton B., Pettay J.D., and Tubbs R.R. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. Appl Immunohistochem Mol Morphol 10 (2002) 1-6
121. Myers J. Automated slide stainers for SS, IHC, and ISH: A review of current technologies and commercially available systems. MLO Med Lab Obs 36 (2004) 28-30
122. Rimsza L.M., Vela E.E., Frutiger Y.M., et al. Rapid automated combined in situ hybridization and immunohistochemistry for sensitive detection of cytomegalovirus in paraffin-embedded tissue biopsies. Am J Clin Pathol 106 (1996) 544-548
123. Lloyd R.V. Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol 14 (2003) 293-301
124. Lloyd R.V. Advances in pituitary pathology: use of novel techniques. Front Horm Res 32 (2004) 146-174